A carregar...
Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis
Background: Leflunomide is the prodrug of the disease modifying antirheumatic metabolite A77 1726. More than 50% of patients withdraw from leflunomide treatment within one year, mainly because of adverse drug reactions. Therapeutic drug monitoring of A77 1726 may be useful in predicting the efficacy...
Na minha lista:
| Main Authors: | , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2005
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1755436/ https://ncbi.nlm.nih.gov/pubmed/15345501 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ard.2004.025205 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|